



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

December 13, 2017

BSE Ltd.
Phiroze Jeejebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code : 506943

Dear Sir,

Sub: Supplementary ANDA approval by US FDA

This is to inform you that US FDA has approved Company's Supplementary Abbreviated New Drug Application (sANDA) for Atenolol Tablets USP 25 mg. 50 mg. and 100 mg. (anti-hypertensive) manufactured using Company's own bulk drug (API). The Company had initiated this change as a part of its plan to gradually backward integrate US formulations business. This approval is expected to boost Company's US sales.

The Company could not commercialize this formulation earlier due to problems associated with external API supplier. This approval will help Company supply these formulations with its own API.

The Company plans to commercialize this product in the next quarter. Currently, the market for this product in US is about US \$ 70 million.

The Company is focused on US business and this approval will help Company grow its exports.

Thanking you,

Yours faithfully,
for J.B. Chemicals & Pharmaceuticals Limited


M. C. Mehta
Company Secretary and Vice President - Compliance